Related Experiment Video

Updated: Jan 6, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

The anti-osteosarcoma property of ailanthone through regulation of miR-126/VEGF-A axis

Daliang Kong1, Boda Ying2, Jinrui Zhang1

  • 1Department of Orthopaedics, China-Japan Union Hospital of Jilin University , Changchun , China.

Artificial Cells, Nanomedicine, and Biotechnology
|October 2, 2019
PubMed

Insights

Ailanthone (AIL) effectively inhibited osteosarcoma cell growth, migration, and invasion. This anti-tumor effect is linked to increased miR-126 and decreased VEGF-A, offering potential therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ailanthone (AIL) shows anti-tumor properties in various cells, but its effect on osteosarcoma remains unknown.
  • Osteosarcoma is a primary bone malignancy with significant unmet therapeutic needs.

Purpose of the Study:

  • To investigate the anti-cancer effects of AIL on the MG63 osteosarcoma cell line.
  • To elucidate the molecular mechanisms underlying AIL's action, focusing on miR-126 and the PI3K/AKT pathway.

Main Methods:

  • Cell proliferation, migration, and invasion assays (CCK-8, BrdU, Transwell) were performed on AIL-treated MG63 cells.
  • Western blot and qRT-PCR were used to analyze protein expression, apoptosis, and miR-126 levels.
  • The regulatory relationship between miR-126 and VEGF-A was investigated.

Main Results:

  • AIL treatment significantly suppressed MG63 cell proliferation, migration, and invasion while inducing apoptosis.
  • AIL upregulated miR-126 expression and inhibited the PI3K/AKT signaling pathway.
  • Osteosarcoma tissues and cell lines exhibited low miR-126 expression; miR-126 silencing attenuated AIL's anti-tumor effects.
  • VEGF-A was identified as a direct target of miR-126.

Conclusions:

  • Ailanthone demonstrates significant anti-proliferative, anti-migratory, and anti-invasive effects on osteosarcoma cells.
  • The anti-tumor activity of AIL is mediated through the upregulation of miR-126, leading to the degradation of VEGF-A.
Keywords:
MG-63 cellPI3K/AKT pathwayapoptosisproliferation

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.1K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.6K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K